Skip to main content
PMC home page
British Medical Journal logoLink to British Medical Journal
. 1972 Apr 22;2(5807):183–188. doi: 10.1136/bmj.2.5807.183

Histological Evidence of Tumour Rejection After Active Immunotherapy in Human Malignant Disease

Geoffrey Taylor, J L I Odili
PMCID: PMC1787938  PMID: 4336763

Abstract

Active immunotherapy with multiple doses of tumour homogenate incorporated in complete Freund adjuvant was used to treat 12 patients with advanced malignant disease. Evidence of some tumour destruction was observed in 10. Improvement in general clinical condition and the disappearance of symptoms referable to tumour occurred in seven of the patients. The duration of improvement varied considerably. Histological evidence of lymphocytic infiltration, necrosis, and fibrous replacement of tumour tissue is presented.

Full text

PDF

Images in this article

184FIG. 1
on p.184
184FIG. 2
on p.184
185FIG. 3
on p.185
185FIG. 4
on p.185
185FIG. 5
on p.185
185FIG. 6
on p.185
185FIG. 7
on p.185
186FIG. 8
on p.186
186FIG. 9
on p.186
186FIG. 10
on p.186
186FIG. 11
on p.186
187FIG. 12
on p.187
187FIG. 13
on p.187

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bansal S. C., Sjögren H. O. "Unblocking" serum activity in vitro in the polyoma system may correlate with antitumour effects of antiserum in vivo. Nat New Biol. 1971 Sep 15;233(37):76–78. doi: 10.1038/newbio233076a0. [DOI] [PubMed] [Google Scholar]
  2. Brandes L. J., Galton D. A., Wiltshaw E. New approach to immunotherapy of melanoma. Lancet. 1971 Aug 7;2(7719):293–295. doi: 10.1016/s0140-6736(71)91336-5. [DOI] [PubMed] [Google Scholar]
  3. Currie G. A., Lejeune F., Fairley G. H. Immunization with irradiated tumour cells and specific lymphocyte cytotoxicity in malignant melanoma. Br Med J. 1971 May 8;2(5757):305–310. doi: 10.1136/bmj.2.5757.305. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. FINNEY J. W., BYERS E. H., WILSON R. H. Studies in tumor autoimmunity. Cancer Res. 1960 Apr;20:351–356. [PubMed] [Google Scholar]
  5. FOLEY E. J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 1953 Dec;13(12):835–837. [PubMed] [Google Scholar]
  6. GORER P. A., KALISS N. The effect of isoantibodies in vivo on three different transplantable neoplasms in mice. Cancer Res. 1959 Sep;19:824–830. [PubMed] [Google Scholar]
  7. GRAHAM J. B., GRAHAM R. M. The effect of vaccine on cancer patients. Surg Gynecol Obstet. 1959 Aug;109(2):131–138. [PubMed] [Google Scholar]
  8. Guyer R. J., Crowther D. Active immunotherapy in treatment of acute leukaemia. Br Med J. 1969 Nov 15;4(5680):406–407. doi: 10.1136/bmj.4.5680.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Hellström I., Hellström K. E. Colony inhibition studies on blocking and non-blocking serum effects on cellular immunity to Moloney sarcomas. Int J Cancer. 1970 Mar 15;5(2):195–201. doi: 10.1002/ijc.2910050205. [DOI] [PubMed] [Google Scholar]
  10. Hellström I., Hellström K. E., Pierce G. E., Yang J. P. Cellular and humoral immunity to different types of human neoplasms. Nature. 1968 Dec 28;220(5174):1352–1354. doi: 10.1038/2201352a0. [DOI] [PubMed] [Google Scholar]
  11. Hellström K. E., Hellström I. Cellular immunity against tumor antigens. Adv Cancer Res. 1969;12:167–223. doi: 10.1016/s0065-230x(08)60331-0. [DOI] [PubMed] [Google Scholar]
  12. KALISS N. Immunological enhancement of tumor homografts in mice: a review. Cancer Res. 1958 Oct;18(9):992–1003. [PubMed] [Google Scholar]
  13. KALISS N., MOLOMUT N. The effect of prior injections of tissue antiserums on the survival of cancer homoiografts in mice. Cancer Res. 1952 Feb;12(2):110–112. [PubMed] [Google Scholar]
  14. KLEIN G., SJOGREN H. O., KLEIN E., HELLSTROM K. E. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960 Dec;20:1561–1572. [PubMed] [Google Scholar]
  15. Klein E. Hypersensitivity reactions at tumor sites. Cancer Res. 1969 Dec;29(12):2351–2362. [PubMed] [Google Scholar]
  16. MURRAY G. Experiments in immunity in cancer. Can Med Assoc J. 1958 Aug 15;79(4):249–259. [PMC free article] [PubMed] [Google Scholar]
  17. Mathé G. Immunological treatment of leukaemias. Br Med J. 1970 Nov 21;4(5733):487–488. doi: 10.1136/bmj.4.5733.487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nadler S. H., Moore G. E. Clinical immunologic study of malignant disease: response to tumor transplants and transfer of leukocytes. Ann Surg. 1966 Sep;164(3):482–490. doi: 10.1097/00000658-196609000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. OLD L. J., BENACERRAF B., CLARKE D. A., CARSWELL E. A., STOCKERT E. The role of the reticuloendothelial system in the host reaction to neoplasia. Cancer Res. 1961 Oct;21:1281–1300. [PubMed] [Google Scholar]
  20. Southam C. M., Brunschwig A., Levin A. G., Dizon Q. S. Effect of leukocytes on transplantability of human cancer. Cancer. 1966 Nov;19(11):1743–1753. doi: 10.1002/1097-0142(196611)19:11<1743::aid-cncr2820191143>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  21. WOODRUFF M. F., NOLAN B. PRELIMINARY OBSERVATIONS ON TREATMENT OF ADVANCED CANCER BY INJECTION OF ALLOGENEIC SPLEEN CELLS. Lancet. 1963 Aug 31;2(7305):426–429. doi: 10.1016/s0140-6736(63)92171-8. [DOI] [PubMed] [Google Scholar]
  22. Wolf P. L., Vazquez J., Czajkowski N. P., Rosenblatt M. A new method of active immunisation to autologous human tumour tissue. Lancet. 1967 Oct 28;2(7522):905–909. doi: 10.1016/s0140-6736(67)90229-2. [DOI] [PubMed] [Google Scholar]
  23. Woodruff M. F., Boak J. L. Inhibitory effect of injection of Corynebacterium parvum on the growth of tumour transplants in isogenic hosts. Br J Cancer. 1966 Jun;20(2):345–355. doi: 10.1038/bjc.1966.42. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES